SOPHiA GENETICS SA (NASDAQ:SOPH – Get Free Report) insider Zhenyu Xu sold 7,394 shares of the business’s stock in a transaction on Monday, October 5th. The stock was sold at an average price of $8.12, for a total value of $60,039.28. Following the sale, the insider owned 545,493 shares of the company’s stock, valued at approximately $4,429,403.16. The trade was a 1.34% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Zhenyu Xu also recently made the following trade(s):
- On Thursday, August 27th, Zhenyu Xu sold 10,000 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $8.91, for a total value of $89,100.00.
- On Thursday, August 13th, Zhenyu Xu sold 4,000 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $7.52, for a total value of $30,080.00.
- On Friday, August 7th, Zhenyu Xu sold 17,000 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $7.29, for a total value of $123,930.00.
- On Wednesday, August 5th, Zhenyu Xu sold 3,000 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $7.00, for a total value of $21,000.00.
- On Tuesday, August 4th, Zhenyu Xu sold 10,000 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $6.92, for a total value of $69,200.00.
- On Monday, July 13th, Zhenyu Xu sold 4,000 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $5.70, for a total transaction of $22,800.00.
SOPHiA GENETICS Trading Down 3.1%
Shares of NASDAQ SOPH traded down $0.23 during mid-day trading on Wednesday, hitting $7.15. The company’s stock had a trading volume of 432,750 shares, compared to its average volume of 308,157. The stock has a market cap of $599.81 million, a price-to-earnings ratio of -6.22 and a beta of 0.95. The company has a debt-to-equity ratio of 0.58, a current ratio of 2.69 and a quick ratio of 2.55. SOPHiA GENETICS SA has a one year low of $3.75 and a one year high of $8.98. The company’s fifty day simple moving average is $7.82 and its 200-day simple moving average is $6.12.
Institutional Trading of SOPHiA GENETICS
Several hedge funds have recently added to or reduced their stakes in the business. Silverberg Bernstein Capital Management LLC lifted its holdings in SOPHiA GENETICS by 8.7% during the first quarter. Silverberg Bernstein Capital Management LLC now owns 51,970 shares of the company’s stock worth $257,000 after acquiring an additional 4,155 shares in the last quarter. Principal Financial Group Inc. increased its holdings in shares of SOPHiA GENETICS by 0.7% in the first quarter. Principal Financial Group Inc. now owns 1,409,242 shares of the company’s stock worth $6,976,000 after acquiring an additional 9,800 shares in the last quarter. First Dallas Securities Inc. bought a new stake in shares of SOPHiA GENETICS in the first quarter worth about $50,000. 1492 Capital Management LLC raised its position in shares of SOPHiA GENETICS by 8.4% during the first quarter. 1492 Capital Management LLC now owns 225,751 shares of the company’s stock worth $1,117,000 after purchasing an additional 17,406 shares during the period. Finally, Royal Bank of Canada raised its position in shares of SOPHiA GENETICS by 3,130.2% during the first quarter. Royal Bank of Canada now owns 19,381 shares of the company’s stock worth $96,000 after purchasing an additional 18,781 shares during the period. Institutional investors and hedge funds own 31.59% of the company’s stock.
Key Headlines Impacting SOPHiA GENETICS
Here are the key news stories impacting SOPHiA GENETICS this week:
- Positive Sentiment: Brokerages reportedly have a consensus price target of $10.00 for SOPHiA GENETICS, suggesting potential upside from recent trading levels if the company meets analyst expectations. SOPHiA GENETICS SA Stock Has Consensus Target Price of $10.00 According to Brokerages
- Neutral Sentiment: A comparison article examined SOPHiA GENETICS against Weave Communications, but the item did not identify a specific new company development or change to SOPH’s outlook. Critical Comparison: Weave Communications vs. SOPHiA GENETICS
- Negative Sentiment: Company insiders collectively sold approximately 82,298 shares worth $668,827, including sales by Chairman Jurgi Camblong, CEO Ross Muken, CFO George Cardoza, CTO Abhimanyu Verma and other executives. The transactions reduced their individual holdings by roughly 0.15% to 3.55%, creating near-term selling pressure and potentially weighing on investor sentiment. However, all reported sales were pre-arranged and explicitly made to satisfy tax obligations rather than indicating discretionary selling. SEC insider transaction filing
Wall Street Analyst Weigh In
A number of research firms recently commented on SOPH. Zacks Research upgraded SOPHiA GENETICS to a “hold” rating in a report on Tuesday, July 21st. BTIG Research raised their target price on SOPHiA GENETICS from $8.00 to $9.00 and gave the stock a “buy” rating in a report on Wednesday, August 5th. Weiss Ratings restated a “sell (d-)” rating on shares of SOPHiA GENETICS in a research report on Friday, July 17th. Finally, HC Wainwright upped their price target on SOPHiA GENETICS from $12.00 to $14.00 and gave the company a “buy” rating in a research note on Wednesday, August 5th. Three analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, SOPHiA GENETICS has a consensus rating of “Hold” and an average target price of $10.00.
Read Our Latest Analysis on SOPH
SOPHiA GENETICS Company Profile
SOPHiA GENETICS is a healthcare technology company that develops cloud-based data analytics solutions for the life sciences and healthcare industries. Its platform is designed to help organizations analyze and interpret complex genomic and multimodal data to support more informed clinical and research decisions.
The company’s principal offering, the SOPHiA DDM platform, combines data management, analytics and artificial intelligence capabilities. It supports applications including cancer genomics, hereditary disease analysis, reproductive health and other areas of precision medicine.
Featured Stories
- Five stocks we like better than SOPHiA GENETICS
- Skydance Just Became a Media Giant—With an $80 Billion Debt Load
- Could Velo3D Be the Next Defense Buyout Target?
- Penguin Solutions Is Soaring as AI Memory Demand Explodes
- Alphabet’s Chart Is Coiling—and the Fundamentals May Be Ready to Back It Up
Receive News & Ratings for SOPHiA GENETICS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SOPHiA GENETICS and related companies with MarketBeat.com's FREE daily email newsletter.
